Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

Cancer

Volumn 97, Issue 1, 2003, Pages 114-120

  Montillo, Marco ^a   Tedeschi, Alessandra ^a   O'Brien, Susan ^b   Di Raimondo, Francesco ^c   Lerner, Susan ^b   Ferrajoli, Alessandra ^b   Morra, Enrica ^a   Keating, Michael J ^b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF TEXAS   (United States)

^c Ferrarotto Hospital   (Italy)

Author keywords

Cladribine; CLL; Cyclophosphamide; PLL

Indexed keywords

CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOSE CALCULATION; DRUG ACTIVITY; DRUG RESPONSE; FEMALE; HUMAN; MALE; MORTALITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; REFRACTORY ANEMIA; TIME; TOXICITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, PROLYMPHOCYTIC; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037214931     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11000     Document Type: Article

References (42)

1. McLaughlin P, Robertson LE, Keating MJ. Fludarabine phosphate in lymphoma: an important new therapeutic agent. Am J Hematol. 1988;29:152-163.
2. Kantarjian HM, Childs C, O'Brien S, et al. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am J Med. 1991;90:223-228.
3. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med. 1993;95:49-52.
4. O'Brien S, Kantarjian H, Keating MJ. Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia. Ann Oncol. 1996;7(suppl 6):S27-S33.
5. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92:1918-1926.
6. Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol. 1996;14:2160-2166.
7. Gandhi V, Kemena A, Keating MJ, et al. Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116-124.
8. Koehl U, Li L, Nowak B, et al. Fludarabine and cyclophosphamide: Synergistic cytotoxicity associated with inhibition of interstrand cross-link removal [abstract]. Proc Am Assoc Cancer Res. 1997;38:2.
9. Bellosillo B, Villamor N, Colomer D, et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood. 1999;94:2836-2843.
10. Koehl U, Ying Yang L, Li L, et al. Effect of combined treatment with 4-hydroperoxycyclophosphamide and fludarabine on cytotoxicity and repair damaged DNA. In: Hiddeman W, Büchner B, Wörmann B, et al. Acute leukemia VII. Experimental approaches and novel therapies. Berlin: Springer-Verlag, 1998:549-555.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
12. Lazzarino M, Orlandi E, Montillo M, et al. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol. 1999;10:59-64.
13. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocyte leukemia. Blood. 1975;46:219-234.
14. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
15. Binet J-L, Auquier A, Dighiero G, et al. A new prognostic classification of CLL derived from multivariate survival analysis. Cancer. 1981;48:198-206.
16. Hallek M, Wilhelm M, Emmerich B, et al. Fludarabine plus cyclophosphamide (FC) and dose intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia: Results of two phase II studies (CLL-2protocol) of the German CLL Study Group (GCLLSG) [abstract]. Blood. 1999;94 (suppl 1):313a.
17. Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: A potentially useful agent in chronic lymphocyitic leukemia. Nouv Rev Fr Hematol. 1988;30:457-459.
18. Keating MJ. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol. 1990;17(suppl 8):49-62.
19. Johnson S, Smith AG, Loffier H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. The French Cooperative Group on CLL. Lancet. 1996;347:1432-1438.
20. Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: Five-year follow-up report. J Clin Oncol. 1997; 15:458-465.
21. Montserrat E, Alcala A, Parody R, et al. Treatmant of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer. 1985;56: 2369-2375.
22. Keating MJ, Hester JP, McCredie KB, Burgess MA, Murphy WK, Freireich EJ. Long term results of CAP therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 1990;2: 391-396.
23. Kempin S, Lee BJ II, Thaler HT, et al. Combination chemotherapy of advanced chronic lymphocytic leukemia: The M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). Blood. 1982;60:1110-1121.
24. Tallman MS, Hakimian D. Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood. 1995;86:2463-2474.
25. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19: 1414-1420.
26. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukemia (CLL): Results of a phase II study of the German CLL Study Group. Br J Haematol. 2001;114:342-348.
27. Saven A, Piro L. 2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia. N Engl J Med. 1994;330:1829-1830.
28. Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SA. In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues-correlation with clinical course. Leukemia. 1998;12:1230-1235.
29. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med. 1992;327:1056-1061.
30. O'Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood. 1994;84:733-738.
31. Saven A, Lemon RH, Piro LD. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med. 1993;328:812-813.
32. Delannoy A, Martiat P, Gala JL, et al. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia. 1995;9:1130-1135.
33. Van Den Neste E, Louviaux I, Michaux JL, et al. Phase I/II study of 2-chloro-2-deoxyadenosine and cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia. 2000;14:1136-1142.
34. Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol. 1999;104:612-613.
35. Weiss M, Spiess T, Berman E, Kempin S. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia. 1994;8:1290-1293.
36. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
37. Laurencet FM, Zulian GB, Guetty-Alberto M, Iten PA, Betticher DC, Alberto P. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer. 1999;79:1215-1219.
38. O'Brien S. Clinical challenges in chronic lymphocytic leukemia. Semin Hematol. 1998;35(suppl 3):22-26.
39. Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: A role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol. 1995;49:135-142.
40. O'Brien S, Kantarjian H, Beran M, et al. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia. 1997;11: 1631-1635.
41. Beutler E, Piro LD, Saven A, et al. 2-chlorodeoxyadenosine (2CdA): A potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma. 1991;5:1-56.
42. Orchard J, Bolam S, Myint H, Oscier DG, Hamblin TJ. In patients with lymphoid tumours recovering from the auto-immune complications of fludarabine, relapse may be triggered by conventional chemotherapy. Br J Haematol. 1998; 102:1112-1113.